Leadership - etira

Home
Our Company
Our Science
Clinical Trial
Our Pipeline
Our Team
News
Contact
Menu Menu

LinkedIn

Home
Our Company
Our Science
Clinical Trial
Our Pipeline
Our Team
News
Contact

There is nothing to show here!

Slider with alias slider-7 not found.

Russell Hayward
Chief Executive Officer

Ganesh V. Raj MD PhD
Founder, Chief Medical Officer & Chief Scientific Officer

Dr. Annalisa Jenkins, OBE
Board Member

Justin Stebbing MD PhD
Board Member
Editor-in-Chief Oncogene, Professor of Biomedical Sciences, ARU Cambridge.

Heather McArthur MD
Clinical Advisory Board
UT Southwestern, Komen Chair in Breast Cancer

Johann de Bono MD PhD
Clinical Advisory Board
Regius Professor Royal Marsden, United Kingdom

Carlos Arteaga MD
Clinical Advisory Board
UT Southwestern Director, Simmons Comprehensive Cancer Center

Rasha Cosman MBBS
Clinical Advisory Board
Head of Early Phase Clinical Trials Unit and the Clinical Lead of Oncology Clinical Trials, at The Kinghorn Cancer Centre

Sharron Gargosky PhD
Australian Regulatory and Clinical Operations

Jung-Mo Ahn PhD
Founder and Chief Chemist

Ratna Vadlamudi PhD
Founder and Animal Models

Paul Wynne PhD
CMC Organic & Analytical Chemistry
PhD Forensic Chemistry, MAppSc Organic Chemistry

Where to find us

Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247

Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

Inclusion criteria:

Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months

Exclusion criteria

Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.